Hamasaki H, Hamasaki Y. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018; 9(10): 165-171 [PMID: 30364744 DOI: 10.4239/wjd.v9.i10.165]
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Hamasaki H, Hamasaki Y. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018; 9(10): 165-171 [PMID: 30364744 DOI: 10.4239/wjd.v9.i10.165]
World J Diabetes. Oct 15, 2018; 9(10): 165-171 Published online Oct 15, 2018. doi: 10.4239/wjd.v9.i10.165
Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
Hidetaka Hamasaki, Yasuteru Hamasaki
Hidetaka Hamasaki, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Kagoshima 890-0046, Japan
Yasuteru Hamasaki, Diabetes, Hamasaki Clinic, Kagoshima 890-0046, Japan
Author contributions: Hamasaki H and Hamasaki Y equally contributed to study conception, data acquisition, data analysis, interpretation, and writing of article.
Institutional review board statement: This study protocol was reviewed and approved by the Japan Medical Association Ethical Review Board.
Informed consent statement: Study participants are assured that collected data will be used only for this study and will not be disclosed without the consent of the participants.
Conflict-of-interest statement: The authors declare no conflict of interest.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hidetaka Hamasaki, MD, PhD, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Nishida 2-21-4, Kagoshima 890-0046, Japan. hhamasaki78@gmail.com
Telephone: +81-99-2503535 Fax: +81-99-2501470
Received: June 25, 2018 Peer-review started: June 25, 2018 First decision: July 9, 2018 Revised: July 12, 2018 Accepted: August 26, 2018 Article in press: August 26, 2018 Published online: October 15, 2018 Processing time: 110 Days and 7.6 Hours
Abstract
AIM
To evaluate the comparative effectiveness of anagliptin and linagliptin on the clinical parameters in patients with type 2 diabetes mellitus (T2DM).
METHODS
A 2-year retrospective cohort study was conducted in patients with T2DM who received anagliptin and linagliptin. We enrolled 234 patients (anagliptin group, 117 patients; linagliptin group, 117 patients).
RESULTS
The glycemic control considerably improved 3, 6, 12, and 24 mo after the administration of both dipeptidyl peptidase-4 (DPP-4) inhibitors. Following the administration of anagliptin, the diastolic blood pressure and serum total cholesterol levels decreased. However, serum high-density lipoprotein cholesterol levels increased and urinary albumin-creatinine ratio decreased following linagliptin administration. Furthermore, the liver function improved after the administration of linagliptin.
CONCLUSION
These findings suggest that that the efficacy of DPP-4 inhibitors on the blood pressure, lipid profile, and liver function differs between anagliptin and linagliptin.
Core tip: Whether a substantial clinical difference exists in the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters remains inconclusive. Although this study is a relatively small-scale, short duration, retrospective study, the findings of this study suggests that the efficacy of DPP-4 inhibitors on the blood pressure, lipid profile, and liver function differs between anagliptin and linagliptin.
